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Drugs: Release of Drugs Covalently Bonded to Poly
mers, J. Parent, DrugAssoa, 32, 188 (1978)]. The release

POROUS MICROSPHERES FOR DRUG
DELIVERY AND METHODS FOR MAKING SAME

of a number of anti~tumor agents has been evaluated in

implantable systems as reported in lYolles, 5., Time
Release Depot for Anticancer Drugs: Release of Drugs
Covalently Bonded to Polymers, J. Parent, Drug Assoc,
32, 188 (1978)], and the antibiotic Mitomycin C has been
encapsulated in microspherical carriers of gelatin and

This application is a continuation of application Ser.
No. 551,414, ?led Nov. 14, 1983, and now abandoned.
BACKGROUND OF THE INVENTION
(1) Field of the Invention
The present invention relates generally to spherical
polymer matrices for the controlled release of various
drug(s) or other selected agents. More particularly, this

Mitomycin C to Liver, Spleen and Lung: Nano-and
Microspherical Carriers of Gelatin. Intern J. Pharm, 81,

invention describes methodology for preparing highly
porous spherical polymer matrices with preselected
incorporated agents, e.g., therapeutics, dispersed within

and the potential for antibiotic targeting discussed. The
size distribution of the microspheres (i.e. 5-30 pm) re

administered intraveneously [Yoshioka, T., Hashida,
M., Muranishi, S., and Sezaki, H., Speci?c Delivery of
131 (1981)]and the effect of size on in vivo distribution
5

the con?nes of the pores therein for controlled delivery

ported in the last mentioned publication was very

to target physiological systems and resulting biodegrad
able microspheric drug carrier or controlled delivery
systems.

broad, especially for intravenous administration. Re
cently the in-vitro release of local anesthetics from
polylactic acid spheres prepared by a solvent evapora
20 tion process has, likewise, been reported [Wakiyama,

(2) State of the Art

A wide variety of microencapsulation drug delivery

N., Kaxuhiko, J., Nakano, M., In?uence of Physico

systems have been developed heretofore for the rate
controlled release of therapeutics or other agents. For

chemical Properties of Polylactic Acid on'the Charac
teristics and In Vitro Release Patterns of Polylactic

instance, considerable research has been devoted to

incorporating therapeutic agents into polyesters such as

25

polye-caprolactone), poly(e-capro1actone-CO-DL-lac

Acid Microspheres Containing Local Anesthetics,
Chem. Pharm. BulL, 30, 2621 (1982)]. The patterns of
release from these polylactic acid spheres were charac
terized by the various degrees of degradation of the

tic acid), poly(DL-lactic acid), poly(DL~lactic acid
CO-glycolic acid) and polye-caprolactone-CO-glycolic

polymer as well as solubilities of loaded drugs although

acid) in which release was diffusion controlled. See, for

no attempt was apparently made to evaluate this param

example, Pitt, C. G. (Pitt, C. G., Gratzl, M. M., Jeffcoat,
A. R., Zweidinger, R., Schindler, A., Sustained Drug
Delivery Systems. II. Factors Affecting Release Rates
from Poly(e-caprolactone) and Related Biodegradable
Polyesters. J. Pharm. Sci, 68, 1534 (1979). These sys

eter. Additionally, it is apparent that the solubility of the
drug played an important role in the rate and extent of

release. Scanning electron photomicrographs also re
vealed varying degrees of erosion and deformation of
the spheres after release.

tems were fabricated as ?lms and capsules and the re

It will be seen from the foregoing that while the

sults suggest that the devices can be prepared to erode

controlled release delivery of pharmaceuticals or other
agents from heretofore described polymeric systems has
been principally limited to oral, topical or implantable

after release of the drug is essentially completed. Degra
dation of at least the polyesters has been reported to

proceed by random hydrolytic cleavage of ester link
systems in which the considerations relative to pore size
ages by an autocatalytic process the rate of chain cleav 40 and/or cell size within the carrier matrix as well as the
age being in?uenced by chemical and morphological
overall dimensions of the microspheres to be adminis
factors.
tered along with the rate of release and the relative
Sustained release systems of antimalarial agents and
absorption rate from a bioavailability standpoint are
sulfadiazine in glycolic-lactic acid copolymers have also
been reported. Wise, D. L., Gesser, J. D., McCormick,

distinctly different from the evaluation parameters in
volved in the utilization of these microsphere delivery

G. J., Sustained Release of a Dual Anti-malarial System,

systems for parenteral, i.e., intravenous, intraarterial,

J. Pharm. Pharmacol., 31, 201 (1979). Wise, D. L., Mc
Cormick, G. J., Willet, G. R, Anderson, L. C., Sus

the present invention is particularly applicable.

intraocular or inhalation administration routes to which

tained Release of an Antimalarial Drug Using a Copoly
mer of Glucolic/Lactic Acid, Life Sci., 19, 867 (1976).
Wise, D. L. , McCormick, G. J., Willet, G. P., Ander
son, L. C., Howes, J. F., J. Pharm. PharmacoL, 30, 686

SUMMARY OF THE INVENTION

It is, therefore, a primary object of the present inven

tion to afford novel porous microspheres for the con
trolled delivery of drugs or other matrix con?ned mate
involved dissolving the agents in a suitable solvent and
rials to target organs or systems in warm-blooded ani
either spray drying or casting ?lms according to usual 55 mals in need thereof and to methods for making such
methods and evaporating the solvent. Various narcotic
microspheres.
antagonists and steroids have been incorporated in ?lms
A further object of the present invention is to provide
and implanted in rats [e.g., see Woodland, J. H. R.,
methods for preparing porous microspheres of hereto
fore unattainable narrow-range size distribution particu
Yolles, 8., Blake, D. A., Helrich, M., Meyer, F.J.,
Long-Acting Delivery Systems for Narcotic An
larly suitable for use as parenterally administerable drug

(1978). Methods reported by the foregoing investigators

tagonists:I. .l Med. Chem, 16, 897 (1973). .Iackanicz, T.
M., Nash, H. A., Wise, D. L., Gregory, J. B., Polylactic

delivery systems for injectable and inhalation dosage

Acid as a Biodegradable Carrier for Contraceptive

more conventional oral administration routes.

Steroids, Contraception, 8, 22.7 (1973). Anderson, L. C.,
Wise, D. L., Howes, J. F., An Injectable Sustained
Release Fertility Control System, Contraception, 13, 375
(1976)] and incorporated into particles injected subcuta
neously [Yo1les, S., Time-Release Depot for Anticancer

forms as well as facilitating sustained drug release via
65

It is a still further object of the present invention to
provide porous microsphere matrices wherein the ac
cessability of the drug or other incorporated agent is not
dependent upon the physical or chemical erosion of the

polymer for release.

3

4,818,542

Another object of the present invention is to provide

chemically modi?ed polymer compositions suitable for
use in the spherical polymer matrices of the invention
whereby porosity as well as degradation of the polymer
substrate after release of the matrix con?ned agent for
release can be predetermined and controlled.
A still further object of the present invention is to

and polylactic (PLA) acids, and copolymers of glyco
lide and L(-lactide) (PGL). The aforementioned polyes
ters are particularly suited for the methods and compo
sitions of the present invention by reason of their char~

acteristically low human toxicity and virtually com
plete biodegradability. Of course, it will be understood
that the particular polyester or other polymer, oligo
mer, copolymer, etc., utilized as the microspheric poly—

provide porous polymeric microspheric drug delivery
systems which allow targeting of drugs or other agents
to speci?c host tissues or cells via injection or inhalation

providing high localized concentrations, sustained ac
tivity, systemic administration and treatment not possi

mer matrix is not critical and a variety of polymers may
be utilized as a consequence of the novel processing

ble by other methods thereby minimizing undesirable
systemic effects of toxic drugs administered directly
into the circulation.

4

ages which are, therefore, bidoegradable. Typically
preferred of such polyesters are polyglycolic (PGA)

methods of the invention which yield the desired micro
15

spheres of the porosity, consistency, shape and size

These and other similar objects, advantages and fea
tures are accomplished according to the methods, prod
ucts and compositions of the present invention.

distribution essentially irrespective of the source 'of
polymer utilized. Accordingly, other biodegradable or
bioerodable polymers or copolymers evidencing the

BRIEF DESCRIPTION OF DRAWINGS
FIG. 1 is a drawing of a polymer with a low degree

necessary low degree of toxicity suitable for use in the

present invention include, for example, gelatin, agar,
starch, arabinogalactan, albumin, collagen, natural and

of crystallinity in accordance with the practice of the

synthetic materials or polymers, such as, poly(e

‘present invention and a drawing of a polymer with a

high degree of crystallinity.
FIG. 2 is a graph of half-life in months versus various 25

caprolactone), poly(e-caprolactone-CO-lactic acid),
poly(e-caprolactone-CO-glycolic acid), poly(B
hydroxy butyric acid), polyethylene oxide, polyethyl~

ratios of polyglycolic (PGA) and polylactic (PLA) as
copolymer implanted in rat tissues.

ene, poly(alkyl-Z-cyanoacrylate), (e.g., methyl, ethyl,

FIG. 3 is graph of percent water uptake versus per

butyl, etc.), hydrogels such as poly(hydroxyethyl meth

cent glycolic acid for glycolide/lactide copolymers.
FIGS. 4A and 4B generally depict the preparative

acrylate), polyamides (e.g., polyacrylamide),
poly(amino acids) (i.e., L-leucine, L-aspartic acid, B
methyl-L-aspartate, B-benzyl-L-aspartate, glutamic

methods of the present invention.
FIGS. 5A and 5B depicts the shape and surface ap

acid and the like), poly(Z-hydroxyethyl DL-asparta

pearance of polyglycolic (PGA) microspheres prepared
by Dilution-Prescriptation Method.

mide), poly(ester urea), poly(L-phenylalanine/ethylene

FIGS. 6A and 6B depicts the shape and surface ap 35 glycol/1,6-diisocyanatohexane) and poly(methyl meth
acrylate).
pearance of PGA microspheres prepared by Freeze

The foregoing exemplary natural and synthetic poly

Dry Method.

mers suitable for use in the present invention are, of
course, either readily available commercially or are

FIG. 7 is a graph of the release pro?le from matrices
which were prepared by Precipitation Method and
contain different amounts of marker.
FIG. 8 is a graph of the release pro?le form matrices
which were prepared by Freeze Dry Method and con

obtainable by condensation polymerization reactions
from the suitable monomers or, comonomers or oligo

tain different amounts of marker.

FIG. 9 is a graph of the release pro?le from matrices
which were prepared by Freeze Dry Method and con 45

tain prednisolone acetate.

FIG. 10 depicts scanning electron micrography
(SEM) micrographs of the PGA matrix manufactured
by Freeze Dry Method 72 hours following drug release.

glycolic/Poly?actic acid) Homo~ and Copolymers: 1,
Polymer, 20, 1459 (1979). Structurally, polyglycolic
acid (PGA) has the following structure:

FIG. 11 depicts SEM micrographs of the PGA ma
trix manufactured by Freeze Dry Method after 120
hours following drug release.
FIG. 12 depicts SEM micrographs of the PGA ma
trix manufactured by Freeze _Dry Method 168 hours

following drug release.

H o

H o

I

I

II

ll
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FIG. 13 is a graph of the release of dye from polymer

II

in plasma.
FIGS. 14A and 14B depict PGL microspheres con

whereas the related copolymer polyglycolic acid/
polylactic acid (PGI; has the structure depicted below:

taining blue dye manufactured by Dilution-Prescipita
tion Method.
FIGS. 15A and 15B depict gelatin microspheres man
ufactured by a modi?ed Dilution-Precipitation Method.
DESCRIPTION OF THE PREFERRED
EMBODIMENTS

mers. For instance, homopolymers and copolymers of
glycolic and lactic acids can be prepared by direct poly
condensation or by reacting glycolide and lactide mon
omers as disclosed by Gilding, D. K., Reed, A. M.,
Biodegradable Polymers for Use in Surgery - Poly

65

The porous polymeric microspheres of the present
invention are derived from copolymeric and homopo

lymeric polyesters containing hydrolyzable ester link

II
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-continued
0

6

ces of microspheres is between about 0.5 to 50 microns.

The integratable methods for preparing porous spheri
cal matrices consistent with the present invention result

in microspheres in which essentially all of the agent(s)
incorporated within the pores of the drug delivery sys
tem is readily available for release. Essentially the fore
II
going principle objective of the invention is accom
plished by forming emulsi?ed droplets or spheres con
Both of the foregoing are polyester type polymers
sisting of a homogeneous mixture of polymer (or 00
which readily degrade via hydrolysis at the ester link
ages and by appropriately selecting suitable molecular l0 polymer), solvent and matrix incorporated agent from a
solution of a preselected polymer and agent dispersed in
weight polyesters, modifying the degree of cross-link
ing and the degree of crystallinity, the biodegradation
a continuous (non-solvent phase). Removal of the sol
properties of such polymers may be advantageously
vent from the sphere by any one or combination of (1)
controlled. As pointed out previously, however, in
freeze drying, or (2) dilution-precipitation extraction,
accordance with the present invention the necessity for 15 creates the interconnecting network of pores wherein
biodegradation or bioerosion of the polymer matrix for
the incorporated agent is con?ned within the walls and
release of the agent incorporated therein to occur is
channels of the pores as opposed to random distribution
obviated by reason of the intrinsic porosity characteris
within the more poorly de?ned interstices of the poly
tics of the polymer matrices of the invention and the
mer. As used in the speci?cation and claims, the expres
fact that the incorporated agent or agents are matrix 20 sion "pore incorporated agen ” is used to de?ne the
con?ned within the interconnecting channels or pores
relative speci?c location of the agent con?ned essen

of the spherical polymer. However, in accordance with
alternative and preferred embodiments of the present

tially completely inside the pores of the porous micro
spheres of the invention. Similarly, the term “agent”
invention the possibility that the matrix could be coated
speci?cally
encompasses any diagnostic or pharmaco
with a ?lm or cross-linking agent to inhibit or control 25 logically active material which would be generally
release, thereby allowing bioerosion to in?uence release
classi?able as a drug suitable for introduction into a
is not in any way precluded and may, in fact, depending
human or other warmblooded animal host, as well as
upon the nature of the incorporated agent as well as the
other materials or compositions including, for instance,
rate of release required in the target organ system may
dyes, antigens, antibodies, enzymes, ?avors, comestibles
be desirable or advantageous. For example, in those
and the like and mixtures thereof.
instances where it may be desirable to inhibit or retard
The drug delivery systems in accordance with the
drug release rates, more extensive cross-linking of the
present
invention are ideally suited for administration
copolymer or polymer may be achieved by the addition
by parenteral or inhalation routes. It will be appreciated
of higher concentrations of suitable cross-linking agents
such as glyoxal, succinaldehyde, glutaraldehyde, 3 35 by those skilled in the art that the porous microspheres
of the present invention containing pore incorporated
methylglutaraldehyde, methyleneacrylamide, bisacryl
drugs for release to target cells or tissues, therefore,
amide and similar cross-linking agents. Likewise, the
may be administered alone or in admixture with appro
reduction or elimination of crosslinks in the copolymers
or polymers of the invention will result in enhanced

priate pharmaceutical diluents, carriers, excipients or

biodegradability. On the basis of such polymer modi?
cations, it is evident that the release of the incorporated
agent or agents will be essentially complete, i.e., 90%

cal practices. For example, for parenteral injection,

adjuvants suitably selected with respect to the intended
route of administration and conventional pharmaceuti

dosage unit forms may be utilized to accomplish intra
venous, intramuscular or subcutaneous administration,
trix occurs, and, thus, the polymer composition can be
preselected to permit controlled clearance from the 45 and for such parenteral administration, suitable sterile
aqueous or non-aqueous solutions or suspensions, op
target system after release of the incorporated drug.
tionally containing appropriate solutes to effectuate
The polymers utilized in accordance with the inven
isotonicity, will be employed. Likewise for inhalation
tion exist in the crystalline form with amorphous re
dosage unit forms, for administration through the
gions interdispersed between the crystalline areas as
shown, for example, in FIG. 1. Hydrolysis rates have 50 mucus membranes of the nose and throat or bronchio
pulmonary tissues, suitable aerosol or spray inhalation
been shown to be higher in the amorphous regions. For
compositions and devices will be utilized.
the copolymers of PLA/PGA, the degree of crystallin
Consistent with other preferred embodiments of the
ity is reduced at a composition of equal amounts of PLA
and PGA. As shown in FIG. 2, the half-life for the
present invention, the porous microspheric drug deliv
degradation of polymer in rat tissue was lowest at a 55 ery systems of the invention may be additionally coated
50-50 composition. FIG. 3 shows that the water uptake
or modi?ed to advantageously in?uence the targeting
is highest in this range which constitutes the amorphous
of the release of the incorporated drug therein to prese
region. Therefore bioerosion occurs in the amorphous
lected target cells, tissues or organs. For example, the
regions initially and eventually the backbone is de
drug delivery microspheres may be coated with various
stroyed and the matrix will collapse, thereby accelerat 60 agents, e.g., proteins, surfactants, antibodies or receptor
ing the bioerosion and elimination of the polymer.
site speci?c drugs which may be the same or different
Consistent with the controlled conditions of the
from those incorporated in the porous microsphere
methods of the present invention, spherical polymer
whereby the release of the incorporated drug is concen
matrices or microspheres having a diameter range be
trated at the targeted system.
before any erosion or degradation of the polymer ma

tween about 1 to 150 microns (um) can be prepared in 65
The preparative methods of the present invention are
narrow size ranges for targeting to various organ or
generally depicted in FIGS. 4A and 4B.

organ systems via parenteral injection or inhalation. A
more preferred range for the spherical polymer matri

In accordance with the methods for making the po
rous microspheres of the invention, the desired polymer

7
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or copolymer and the drug(s) or other agent(s) are
dissolved separately in a suitable solvent. The polymer

drofuran, hexane, benzene. Solvents for the continuous
phase should not dissolve the polymer and should emul

and drug solutions are mixed together in the appropri
ate manner to provide a polymer concentration ranging

oxane, acetone, methylene chloride, chloroform, car

sify the dispersed phase. Solvents include benzene, di

between about 2.5 to 18% w/w and a drugzpolymer
ratio ranging between about 1:1 to 1:10. The tempera
ture of the resultant solution is controlled between

bon tetrachloride, toluene, ethyl alcohol, acetonitrile,

about 30'-45° C. The drug-polymer solution compris
ing the dispersed phase is dispersed into the continuous
phase containing an appropriate surface active agent at
a thermostatically controlled temperature generally in
the range of l0°-20° C. The foregoing is accomplished
by forcing the dispersed phase under pressure through a
?ne ori?ce nozzle. The continuous phase which is 10-20
times by weight of the dispersed phase is then agitated
by a dispersator. Following the introduction of the
dispersed phase, one of two recovery methods (see

A diluent (non-solvent) phase can also be employed
to dilute the continuous phase following dispersion of
the polymeragent solution. The diluent should be misci
ble with the continuous phase and dispersed phase sol
vents ‘but not dissolve the polymer or incorporated

p-xylene, tetrahydrofuran and mixtures of these sol
vents.

agent. Examples of solvents include 1,4.dioxane, cyclo
hexanone, acetone, ethanol, acetonitrile, dimethylform
amide, tetrahydrofuran and cyclohexanol.
The concentration of polymer in the dispersed phase
directly influences the porosity or “void” space in the
?nal microsphere product as well as the shape of the
microsphere. A concentration of 2.5% to 10% w/w

FIG. 4) is utilized to stabilize and recover the drug

loaded microspheres for final processing.
More speci?cally, consistent with the freeze-dry
method of the invention, following dispersion, the tem
perature is maintained at l0°-20° C., preferably 15‘ C.,

'

20

polymer yields dimensionally suitable spherical parti
cles. With respect to the concentration of the pore in

corporated agent, up to 50% by weight of the polymer

has been achieved with consistent results.
In accordance with another preferred embodiment of
of the mixture is continued during this period. When the 25 the present invention, hydrophilic colloids are em
ployed to improve the yield and prevent phase inver
temperature reaches 50“ C., either a refrigerant solution
sion in the continuous and diluent phases. Substances
is circulated through the jacket from the bath or the
which can be utilized in concentrations ranging be
container is immersed in dry ice-methanol and cooled to
tween about 0.5 to 5% include anionic surfactants such
a temperature which will freeze the drug-polymer-sol
as sorbitan, gelatin and gelatin derivatives, polyvinyl
vent phase and not the continuous phase. The suspen

for two minutes then increased to 45°—55° C., preferably
50" C., over a three minute period. Vigorous agitation

sion or emulsion (solid dispersion phase in liquid contin
uous phase) is quickly transferred to precooled vials

alcohol, polystyrene sulfonate, hydroxyethylcellulose,

(—40° to —60° C.) and cooled to —40° to —60° C. in a
freeze dryer, freezer or dry ice-acetone bath. The sol

able hydrophilicity.

vent in the suspended droplets (microspheres) and the
continuous phase solvent are removed by freeze drying.
Upon completion of the freeze dry cycle the micro

eters influence the recovery methods as well as the

spheres are washed with a suitable solvent, ?ltered and
air dried.

hydroxypropylcellulose and related colloids with suit
.

It has been determined that certain processing param

resultant microspheres of the present invention. Identi
?able parameters include the concentration of polymer
in the dispersed phase, the temperature of the dispersed
phase at the time of dispersion, the concentration of

In the dilution-precipitation method of the invention, 40 surfactants in the dispersed phase as well as the ratio of
incorporated agent to polymer in the dispersed phase. It
following dispersion, the temperature is maintained at
will be appreciated that the concentrations, tempera
l0°-20' C., preferably 15' C., for two minutes, then
tures and ratios referred to hereinabove and in the Ex
increased to 45°—55° C., preferably 50° C., over a three
amples set forth operable ranges and that other numeri
minute period. The dispersion is then transferred to a
vessel containing a diluent solvent at room temperature 45 cal expressions may apply as different solvents, poly
mers, incorporated agents, etc. are selected.
as depicted in FIG. 4. Agitation is continued for 30
The shape and surface appearance of microspheres
minutes using a vibromixer. During the process the
prepared in accordance with the recovery methods of
dispersed phase solvent is removed from the drug~
the invention were assessed by Scanning Electron Mi
polymer-solvent emulsion droplets by extraction caus
ing solidi?cation of the droplets. The solid spheres are 50 croscopy (SEM), FIGS. 5-7 as well as by optical mi
crography.
then removed by ?ltration, washed with a suitable sol
Typical release pro?les are also shown in FIGS. 7-9
vent and air dried.

Solvents for the dispersed phase and the continuous

. The very water soluble FD&C dye Blue #1 releases

phase will of course differ in order to attain phase sepa~
ration and, are therefore, selected based upon the sol

within l~3 days depending upon the concentration of
dye (i.e., marker). In all instances release is completed
before discernible degradation or erosion of the matrix

vent requirements for each phase. More particularly,
occurs. FIGS. 10 and 11 show SEM micrographs of the
the solvent for the dispersed phase should dissolve the
spheres following 72 hours and 120 hours, respectively,
polymer and the incorporated agent and remain in the
in the dissolution media. The spheres were essentially
emulsi?ed droplets with the drug and polymer in the
continuous phase until leached out by a diluent solvent 60 intact indicating minimal erosion. The release of a less
soluble compound, prednisolone acetate is shown in
or removed by vaporization or evaporation. In this way
FIG. 9. Essentially 90% of the drug was released after
pores are formed in the drug-polymer matrix. In the
7 days and degradation of the matrix was very evident
case of PGA polymer into which water soluble markers
after 7 days as shown by the fragmentation in FIG. 12.
or agents are incorporated, hexa?uoroacetone sesquihy
drate (EPA) is an appropriate solvent. Other solvents 65 The following non-limiting Examples are afforded in
which can be used, depending upon characteristics of

order that those skilled in the art may more readily

polymer and incorporated agents, include water, hexa

understand the present invention and speci?c preferred

fluoroisopropanol (HFIP), methylene chloride, tetrahy

embodiments thereof with respect to the methods and

4,818,542
compositions in accordance with the foregoing descrip

10

2.0 g of each solution were mixed together and main
tained at 37° C.

tion.
EXAMPLE 1
FD&C Blue #1 - PGA microspheres (freeze dry

DisErsed Phase Concentrations:

recovery)

DRUG

POLYMER

20 mg

200 mg

SOLVENT

3780 mg
1. 0.1 g of FD&C Blue #1 was dissolved in 9.9 g of
0.5%
5.0%
94.5%
HFA to make a 1% (w/w) solution.
2. 1.0 g of PGA was dissolved in 9.0 g of HFA to make
10 4-9. Steps four through nine were the same as in Exam
a 10% (w/w) solution.
ple 1.
3. Equal weights of the above are mixed together to
Spheres obtained by the freeze dry were washed
form the dispersed phase. The resultant spheres from
twice with 125 ml volumes of acetone and collected on
this combination are very porous having 94.5%
0.8, l0, 8!. 50 pm ?lters. The spheres obtained by the
“void” space and a dye-polymer ratio of 1:10. In this
precipitation method were washed with acetone in the
example 2.0 g of each solution were mixed together

size ranges previously obtained by ?ltration and col
lected on 0.8, 10, 8t 50 um ?lters. Washing removes
approximately 8.5% of the dye or drug from the sphere.

and maintained at 37° C. The spherical microporous
polymeric network has a degree of porosity of be
tween about 80 to 98 percent as determined by rela
tive void space in relation to the starting concentra

EXAMPLE 3

tion of the polymer.

Characterization of Microporous Microspheres and
Release of Model Compounds

DisErsed Phase Concentrations:
DYE

POLYMER

SEM Photomicrographs of Examples, 1, and 2 are

SOLVENT

20 mg

200 mg

3780 mg

0.5%

5.0%

94.5%

'

25 shown in FIGS. 5-7 at 10-fold differences in magni?ca

tion. The porous nature is evident from the topography
of the magni?ed surfaces of both methods of prepara
tion.
In-vitro release from the microspheres was deter

4. ‘The continuous phase constituted 160 g of CC14 con

taining 0.1% sorbitan sesquioleate (SO-15) which was

mined in 0.1M phosphate buffer (pH 7.4). The spheres

maintained at 15° C. in a 500 ml jacketed vessel. A
dispersator was located at the center of the vessel for

were quantitatively transferred to a 15 ml cuvette tube
with a screw cap and the buffer added. The tubes were
placed on a rocker-type shaker in an oven at 37° C. The

mixing.

5. The dye-polymer-solvent solution was then dispersed
via pressure through a ?ne ori?ce into the continuous 35 tubes were centrifuged at various times and solution
samples were removed for spectrophotometric analysis
_ phase which was agitated vigorously with the disper
at 630 nm for FD&C Blue #1 and at 245 nm for prednis
olone acetate. Release pro?les are shown in FIGS. 7_9

sator. The temperature was maintained at 15° C. and

the mixing continued for 2 minutes. The temperature

for Examples 1 and 2 along with the pro?les of other

was then increased to 50° C. over a 3 minute period

compositions. The release of water soluble dye was

by either circulating 70° C. water through the jacket

essentially complete in 2 to 3 days with spheres pre
pared by the precipitation and freeze dry methods while
the less-soluble prednisolone acetate releases much

(or immersing the vessel in a 70° C. water bath).
6. When the temperature reached 50°, a refrigerant
solution at —22° C. was circulated through the jacket
to freeze the dispersed phase and not the continuous

phase (f.p. of CCl4= —22.6°).

more slowly, 90% in 7 days.
In experiments at a ?xed level of dye, i.e., 4% (by
45

pre-cooled (ca --45° C.) 50 m1 vials and cooled to

weight of polymer) and variable polymer concentration
in the dispersed phase (2.5%, 5% & 10%), the release

-—40° to ~50‘ on the shelves in a freeze dryer which

rate was reduced in relation to the polymer concentra

7. The above suspension was quickly transferred to

tion (FIG. 13). The “void” space or the porosity is

had been precooled to —50° C.

controlled by the polymer (or solvent) concentration of

8. The suspension was maintained at —50° for 1 hour.

the dispersed phase.

Vacuum was applied and the shelves heated to —- 10°

C. and maintained at this temperature for 24 hours to
remove the CC14. The temperature of shelves was
increased to 20° C. for 24 hours to remove the HFA.
The temperature of the shelves was increased to 35°
and maintained for 2 hours to ensure removal of all
solvent.
9. The vials containing the spheres were removed from

EXAMPLE 4
FD&C Blue #1 - PGL microspheres

(Dilution-Precipitation Recovery)
1. 0.1 g of FD&C Blue #1 was dissolved in 9.9 g of
HFA to make a 1% (w/w) solution.
2. 0.5 g of polygalactin 910 (VicrylR) was dissolved in
4.5 g of HFA to make a 10% (w/w) solution.

the chamber and stoppered pending washing and
evaluation.

60 3. Equal weights of the above were mixed together to

EXAMPLE 2

form the dispersed phase and maintained at 37° C.

Prednisolone acetate-PGA microspheres (freeze dry

recovery)
0.1 g of predonisolone acetate was dissolved in 9.9 g of 65
HFA to make a 1% w/w solution.
1.0 g of PGA was dissolved in 9.0 g of HFA to make a

10% w/w solution.

Dispersed Phase Concentrations:
DYE

POLYMER

SOLVENT

20 mg

200 mg

3780 mg

0.5%

5.0%

94.5%

